Cargando…

Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer?

Introduction: Patients with acute coronary syndrome (ACS) and atrial fibrillation (AF) treated with percutaneous coronary intervention (PCI) are at high risk of bleeding and thromboembolic events. Thus, optimal treatment strategies in this challenging subset have been controversial. Herein, we aim t...

Descripción completa

Detalles Bibliográficos
Autores principales: Bachorski, Witold, Bychowski, Jakub, Gruchała, Marcin, Jaguszewski, Miłosz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572308/
https://www.ncbi.nlm.nih.gov/pubmed/37835798
http://dx.doi.org/10.3390/diagnostics13193055
_version_ 1785120204615843840
author Bachorski, Witold
Bychowski, Jakub
Gruchała, Marcin
Jaguszewski, Miłosz
author_facet Bachorski, Witold
Bychowski, Jakub
Gruchała, Marcin
Jaguszewski, Miłosz
author_sort Bachorski, Witold
collection PubMed
description Introduction: Patients with acute coronary syndrome (ACS) and atrial fibrillation (AF) treated with percutaneous coronary intervention (PCI) are at high risk of bleeding and thromboembolic events. Thus, optimal treatment strategies in this challenging subset have been controversial. Herein, we aim to investigate different triple antithrombotic treatment (TAT) strategies in patients with ACS and AF after PCI. Methods: This was a retrospective, single-center study based on all consecutive patients with the diagnosis of ACS and AF treated with vitamin K antagonists (VKA) or non-vitamin K antagonist oral anticoagulants (NOAC) plus dual antiplatelet therapy using a P2Y12 inhibitor (clopidogrel) and aspirin (for 1 to 3 months) and observed for 12 months for major adverse cardiac events (MACE) and major or clinically relevant non-major bleeding incidents. Results: MACE occurred in 26.6% of patients treated with the VKA and 30.9% with NOAC (p = 0.659). Bleeding occurred in 7.8% of patients treated with VKA and 7.4% with NOAC (ns). Conclusions: Among patients with ACS and AF who had undergone PCI, there was no significant difference in the risk of bleeding and ischemic events among those who received TAT with NOAC and VKA.
format Online
Article
Text
id pubmed-10572308
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-105723082023-10-14 Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer? Bachorski, Witold Bychowski, Jakub Gruchała, Marcin Jaguszewski, Miłosz Diagnostics (Basel) Brief Report Introduction: Patients with acute coronary syndrome (ACS) and atrial fibrillation (AF) treated with percutaneous coronary intervention (PCI) are at high risk of bleeding and thromboembolic events. Thus, optimal treatment strategies in this challenging subset have been controversial. Herein, we aim to investigate different triple antithrombotic treatment (TAT) strategies in patients with ACS and AF after PCI. Methods: This was a retrospective, single-center study based on all consecutive patients with the diagnosis of ACS and AF treated with vitamin K antagonists (VKA) or non-vitamin K antagonist oral anticoagulants (NOAC) plus dual antiplatelet therapy using a P2Y12 inhibitor (clopidogrel) and aspirin (for 1 to 3 months) and observed for 12 months for major adverse cardiac events (MACE) and major or clinically relevant non-major bleeding incidents. Results: MACE occurred in 26.6% of patients treated with the VKA and 30.9% with NOAC (p = 0.659). Bleeding occurred in 7.8% of patients treated with VKA and 7.4% with NOAC (ns). Conclusions: Among patients with ACS and AF who had undergone PCI, there was no significant difference in the risk of bleeding and ischemic events among those who received TAT with NOAC and VKA. MDPI 2023-09-26 /pmc/articles/PMC10572308/ /pubmed/37835798 http://dx.doi.org/10.3390/diagnostics13193055 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Bachorski, Witold
Bychowski, Jakub
Gruchała, Marcin
Jaguszewski, Miłosz
Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer?
title Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer?
title_full Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer?
title_fullStr Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer?
title_full_unstemmed Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer?
title_short Two Approaches to Triple Antithrombotic Therapy in Patients with Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Treated with Percutaneous Coronary Intervention: Which Is More Efficient and Safer?
title_sort two approaches to triple antithrombotic therapy in patients with acute coronary syndrome and non-valvular atrial fibrillation treated with percutaneous coronary intervention: which is more efficient and safer?
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572308/
https://www.ncbi.nlm.nih.gov/pubmed/37835798
http://dx.doi.org/10.3390/diagnostics13193055
work_keys_str_mv AT bachorskiwitold twoapproachestotripleantithrombotictherapyinpatientswithacutecoronarysyndromeandnonvalvularatrialfibrillationtreatedwithpercutaneouscoronaryinterventionwhichismoreefficientandsafer
AT bychowskijakub twoapproachestotripleantithrombotictherapyinpatientswithacutecoronarysyndromeandnonvalvularatrialfibrillationtreatedwithpercutaneouscoronaryinterventionwhichismoreefficientandsafer
AT gruchałamarcin twoapproachestotripleantithrombotictherapyinpatientswithacutecoronarysyndromeandnonvalvularatrialfibrillationtreatedwithpercutaneouscoronaryinterventionwhichismoreefficientandsafer
AT jaguszewskimiłosz twoapproachestotripleantithrombotictherapyinpatientswithacutecoronarysyndromeandnonvalvularatrialfibrillationtreatedwithpercutaneouscoronaryinterventionwhichismoreefficientandsafer